Indevus To Market Nebido In The U.S. Upon Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Indevus expects to file an NDA for the injectable testosterone therapy, licensed from Schering AG, for the treatment of hypogonadism in the second half of 2006.